Adela Mazo
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Physiology top 5%
- Adenosine and Purinergic Signaling
Papers in
- Oncology 14
- Cancer-related Molecular Pathways 5
- Pancreatic and Hepatic Oncology Research 4
- Cancer Cells and Metastasis 3
-
- Connexins and lens biology 2
- Co-authors
- Gabriel Capellá (3 shared papers)Marçal Pastor‐Anglada (4 shared papers)F. Javier Casado (2 shared papers)José Manuel García-Manteiga (2 shared papers)Míriam Molina‐Arcas (1 shared paper)Ramón Mangues (1 shared paper)Sergio A. Guerrero (1 shared paper)Lourdes Farré (1 shared paper)
- Journals
- Cancer Gene Therapy (2 papers)Molecular Cancer Therapeutics (1 paper)Human Gene Therapy (1 paper)Clinical Cancer Research (1 paper)Stem Cell Research (1 paper)
- Partner nations
- SpainUnited States
In The Last Decade
Adela Mazo
20 papers receiving 798 citations
Peers
Comparison fields: 5 of 83
- Oncology 520
- Physiology 55
- Cancer Research 135
- Biotechnology 68
- Pathology and Forensic Medicine 108
Countries citing papers authored by Adela Mazo
This map shows the geographic impact of Adela Mazo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adela Mazo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adela Mazo more than expected).
Fields of papers citing papers by Adela Mazo
This network shows the impact of papers produced by Adela Mazo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adela Mazo. The network helps show where Adela Mazo may publish in the future.
Co-authors
The 25 scholars most cited alongside Adela Mazo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. | 2000 | 205 |
| 2 | Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. | 2003 | 174 |
| 3 | 2002 | 72 | |
| 4 | Ras-dependent oncolysis with an adenovirus VAI mutant. | 2003 | 56 |
| 5 | 2008 | 40 | |
| 6 | 2000 | 35 | |
| 7 | 2001 | 32 | |
| 8 | 2011 | 30 | |
| 9 | 2001 | 28 | |
| 10 | 2004 | 28 | |
| 11 | 2011 | 20 | |
| 12 | 2015 | 17 | |
| 13 | 2005 | 16 | |
| 14 | 2013 | 11 | |
| 15 | 2006 | 11 | |
| 16 | 2004 | 11 | |
| 17 | 1993 | 11 | |
| 18 | 1987 | 5 | |
| 19 | 2016 | 4 | |
| 20 | 1986 | 4 |
About Adela Mazo
Adela Mazo is a scholar working on Oncology, Molecular Biology, Genetics, Biotechnology and Materials Chemistry, having authored 20 papers that have together received 810 indexed citations. Recurring topics across this work include Virus-based gene therapy research (7 papers), Cancer Research and Treatments (6 papers), Cancer-related Molecular Pathways (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer Cells and Metastasis (3 papers), Adenosine and Purinergic Signaling (2 papers), Connexins and lens biology (2 papers) and Enzyme Structure and Function (2 papers). The work is most often cited by research in Oncology (520 citations), Physiology (55 citations), Cancer Research (135 citations), Biotechnology (68 citations) and Pathology and Forensic Medicine (108 citations). Adela Mazo has collaborated with scholars based in Spain and United States. Frequent co-authors include Gabriel Capellá, Marçal Pastor‐Anglada, F. Javier Casado, José Manuel García-Manteiga, Míriam Molina‐Arcas, Ramón Mangues, Sergio A. Guerrero, Lourdes Farré, Isolda Casanova and Manel Cascalló. Their work appears in journals such as Cancer Gene Therapy, Molecular Cancer Therapeutics, Human Gene Therapy, Clinical Cancer Research and Stem Cell Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.